Genetic diseases

Disabled patient having rehabilitation
#Gene therapy #Genetic diseases #Genetics / genomics #Muscles

Researchers discover treatment for rare muscle disease

Israeli researchers have developed a drug that is effective in treating a rare genetic muscle disease. The research team from Ben-Gurion University of the Negev and Soroka Medical Center discovered the severe hereditary muscle disease that develops around the age of 40 years, progressing to complete… Read More

#News

Gene therapy
#AAV #EMA #Gene therapy #Genethon #Genetic diseases #Liver disease #Priority Review

Gene therapy for rare liver disease gets EMA priority status

The European Medicines Agency (EMA) has granted PRIME (Priority Medicines) status to the gene therapy, GNT-0003, currently in clinical trials for Crigler-Najjar syndrome, a rare liver disease.   This status, granted only to drug candidates with major therapeutic potential, follows the successful completion of the first phases of the clinical trials. … Read More

#Editor's Choice #News #Regulatory

Human neurone
#Biosciences #Genetic diseases #Ion channels #Neurology #Neuroscience #Rare disease #Therapeutics

Ion channel modulators for ultra-rare genetic disorder 

Metrion Biosciences, a specialist ion channel contract research and drug discovery company, and The KCNC1 Foundation, a not-for-profit organisation focused on the development of a treatment for an ultra-rare genetic disorder, have entered a collaboration to progress a hit identification research project for small molecule modulators of the potassium… Read More

#News

Illustration of a virus
#Gene therapy #Genetic diseases #Immunology / Virology & Vaccines #Virus mutation

Ancient viruses may hold key to gene therapy treatments

Scientists have unlocked key insights into virus evolution, revealing new information that could help develop treatments for a wide variety of genetic diseases.  The research focuses on a group of small, ubiquitous viruses called ‘parvoviruses’ (from the Latin word ‘parvus’ meaning ‘small’, ‘puny’ or ‘unimportant’). Read More

#Editor's Choice #News

#FDA #Genetic diseases #Genetics #R&D

Sitting down with BridgeBio Pharma

Listen to this article on the DDW Podcast: Michael Henderson, MD, Chief Business Officer of BridgeBio Pharma, tells Lu Rahman about the company’s pursuit of transformative medicines to treat genetic diseases. BridgeBio’s mission is to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and… Read More

#Exclusive Content #Opinion